Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported data from a phase 1 / 2 study of once a week investigational MLN9708 in combination with standard dose lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma .
http://www.businesswire.com/news/topix/20121209005046/en
http://www.businesswire.com/news/topix/20121209005046/en
No comments:
Post a Comment